2024
Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reduction
2023
Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status
Rabe K, Pavord I, Busse W, Chupp G, Izuhara K, Altincatal A, Gall R, Pandit‐Abid N, Deniz Y, Rowe P, Jacob‐Nara J, Radwan A. Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy 2023, 78: 2148-2156. PMID: 37073882, DOI: 10.1111/all.15747.Peer-Reviewed Original ResearchConceptsParent study baselineType 2 inflammationPre-bronchodilator FEVAsthma exacerbation rateType 2 asthmaAllergic asthmaExacerbation rateSevere asthma exacerbation ratesSevere type 2 asthmaAsthma Control Questionnaire scoreACQ-5 scoresReduced exacerbation ratesLong-term outcomesLong-term treatmentAllergic statusDupilumab efficacyGINA guidelinesQUEST studyWeek 96Asthma controlUncontrolled asthmaWeek 48Allergic phenotypeLung functionQuestionnaire scores